How often is aranesp given for anemia?

How often is Aranesp given for anemia?

Aranesp (darbepoetin alfa) is given once every one to three weeks by injection, depending on the patient's hemoglobin level, hemoglobin response, and cause of anemia. The exact schedule is adjusted by a doctor to keep hemoglobin in a safe range rather than raising it to a fixed target.

How does the dosing schedule differ for chronic kidney disease patients?

For CKD patients not on dialysis, Aranesp is often given every two weeks. When patients are already on dialysis, it may be given every week or once every two weeks. Doctors monitor hemoglobin closely and reduce frequency or dose if levels rise too fast.

What is the schedule for cancer patients receiving chemotherapy?

Cancer patients who are still receiving chemotherapy get Aranesp once every week or once every three weeks. 一旦 chemotherapy ends, doctors usually discontinue the drug rather than continue indefinitely.

When does the Aranesp patent expire?

The primary U.S. patent covering Aranesp was 6,180,751, covering the molecule itself, which expired in 2018. The biologics price competition and innovation act allows biosimilars to enter after 12 years of exclusivity, which expired in 2013. Current active patents on formulations and manufacturing are listed on DrugPatentWatch.com.

Why are companies challenging remaining Aranesp patents?

Some companies seek to launch biosimilars of darbepoetin alfa before full patent expiry. They challenge formulation patents rather than the core molecule itself, so they can enter the market sooner under the BPCIA pathway.